Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis.

Kaushansky N, Eisenstein M, Zilkha-Falb R, Ben-Nun A.

Autoimmun Rev. 2010 Feb;9(4):233-6. doi: 10.1016/j.autrev.2009.08.002. Epub 2009 Aug 13. Review.

PMID:
19683076
4.
5.

HLA-DQB1*0602 determines disease susceptibility in a new "humanized" multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice.

Kaushansky N, Altmann DM, Ascough S, David CS, Lassmann H, Ben-Nun A.

J Immunol. 2009 Sep 1;183(5):3531-41. doi: 10.4049/jimmunol.0900784. Epub 2009 Jul 31.

7.
8.

The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS).

Kaye JF, Kerlero de Rosbo N, Mendel I, Flechter S, Hoffman M, Yust I, Ben-Nun A.

J Neuroimmunol. 2000 Jan 24;102(2):189-98.

PMID:
10636488
9.

Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen.

Diaz-Villoslada P, Shih A, Shao L, Genain CP, Hauser SL.

J Neuroimmunol. 1999 Sep 1;99(1):36-43.

PMID:
10496175
10.

DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP).

Kaushansky N, Altmann DM, David CS, Lassmann H, Ben-Nun A.

J Neuroinflammation. 2012 Feb 8;9:29. doi: 10.1186/1742-2094-9-29.

11.

A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.

Madsen LS, Andersson EC, Jansson L, krogsgaard M, Andersen CB, Engberg J, Strominger JL, Svejgaard A, Hjorth JP, Holmdahl R, Wucherpfennig KW, Fugger L.

Nat Genet. 1999 Nov;23(3):343-7.

PMID:
10610182
12.

Pathogenic T cells in MOBP-induced murine EAE are predominantly focused to recognition of MOBP21F and MOBP27P epitopic residues.

Kaushansky N, Zilkha-Falb R, Hemo R, Lassman H, Eisenstein M, Sas A, Ben-Nun A.

Eur J Immunol. 2007 Nov;37(11):3281-92.

13.

HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopes.

Finn TP, Jones RE, Rich C, Dahan R, Link J, David CS, Chou YK, Offner H, Vandenbark AA.

J Neurosci Res. 2004 Oct 1;78(1):100-14.

PMID:
15372502
14.
15.

Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.

Kerlero de Rosbo N, Hoffman M, Mendel I, Yust I, Kaye J, Bakimer R, Flechter S, Abramsky O, Milo R, Karni A, Ben-Nun A.

Eur J Immunol. 1997 Nov;27(11):3059-69.

PMID:
9394837
16.

Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.

Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J.

J Mol Med (Berl). 1997 Feb;75(2):77-88. Review.

PMID:
9083925
18.

T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells.

Forsthuber TG, Shive CL, Wienhold W, de Graaf K, Spack EG, Sublett R, Melms A, Kort J, Racke MK, Weissert R.

J Immunol. 2001 Dec 15;167(12):7119-25.

20.

T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.

Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C.

Glia. 2001 Nov;36(2):220-34. Review.

PMID:
11596130

Supplemental Content

Support Center